Ridgewood Investments LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 54.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,097 shares of the biopharmaceutical company’s stock after selling 7,268 shares during the quarter. Ridgewood Investments LLC’s holdings in Pfizer were worth $316,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Econ Financial Services Corp acquired a new position in Pfizer in the fourth quarter valued at about $31,000. PYA Waltman Capital LLC acquired a new position in Pfizer in the fourth quarter valued at about $31,000. Rinkey Investments acquired a new position in Pfizer in the fourth quarter valued at about $32,000. TFO TDC LLC lifted its stake in Pfizer by 126.9% in the fourth quarter. TFO TDC LLC now owns 667 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 373 shares during the period. Finally, Bivin & Associates Inc. acquired a new position in Pfizer in the fourth quarter valued at about $37,000. 66.50% of the stock is currently owned by institutional investors and hedge funds.
PFE opened at $49.07 on Thursday. The stock has a market cap of $275.33 billion, a PE ratio of 11.25, a P/E/G ratio of 0.56 and a beta of 0.76. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. Pfizer Inc. has a 52 week low of $38.82 and a 52 week high of $61.71. The business’s fifty day simple moving average is $50.57 and its 200 day simple moving average is $52.22.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Friday, May 13th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.26%. Pfizer’s dividend payout ratio (DPR) is currently 36.70%.
Several brokerages have issued reports on PFE. Wells Fargo & Company lowered their price target on Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. The Goldman Sachs Group set a $51.00 price target on Pfizer in a report on Wednesday, May 25th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. Morgan Stanley began coverage on Pfizer in a report on Wednesday, April 6th. They issued an “equal weight” rating and a $55.00 price target for the company. Finally, Berenberg Bank set a $50.00 price target on Pfizer in a report on Friday, May 27th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.26.
In related news, SVP Jennifer B. Damico sold 4,218 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at $585,250.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares in the company, valued at $1,907,300. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock worth $2,075,003 over the last ninety days. Insiders own 0.05% of the company’s stock.
Pfizer Company Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.